Skip to main content

Research Repository

Advanced Search

Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease

Batson, Jennifer; Toop, Hamish D.; Redondo, Clara; Babaei-Jadidi, Roya; Chaikaud, Apirat; Wearmouth, Stephen F.; Gibbons, Brian; Allen, Claire; Tallant, Cynthia; Zhang, Jingxue; Du, Chunyun; Hancox, Jules C.; Hawtrey, Tom; Da Rocha, Joana; Griffith, Renate; Knapp, Stefan; Bates, David O.; Morris, Jonathan C.

Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease Thumbnail


Authors

Jennifer Batson

Hamish D. Toop

Clara Redondo

Apirat Chaikaud

Stephen F. Wearmouth

Brian Gibbons

Claire Allen

Cynthia Tallant

Jingxue Zhang

Chunyun Du

Jules C. Hancox

Tom Hawtrey

Joana Da Rocha

Renate Griffith

Stefan Knapp

DAVID BATES David.Bates@nottingham.ac.uk
Professor of Oncology

Jonathan C. Morris



Abstract

Serine/arginine-protein kinase 1 (SRPK1) regulates alternative splicing of VEGF-A to pro-angiogenic isoforms and SRPK1 inhibition can restore the balance of pro/antiangiogenic isoforms to normal physiological levels. The lack of potency and selectivity of available compounds has limited development of SRPK1 inhibitors, with the control of alternative splicing by splicing factor-specific kinases yet to be translated. We present here compounds that occupy a binding pocket created by the unique helical insert of SRPK1, and trigger a backbone flip in the hinge region, that results in potent (<10 nM) and selective inhibition of SRPK1 kinase activity. Treatment with these inhibitors inhibited SRPK1 activity and phosphorylation of serine/arginine splicing factor 1 (SRSF1), resulting in alternative splicing of VEGF-A from pro-angiogenic to antiangiogenic isoforms. This property resulted in potent inhibition of blood vessel growth in models of choroidal angiogenesis in vivo. This work identifies tool compounds for splice isoform selective targeting of pro-angiogenic VEGF, which may lead to new therapeutic strategies for a diversity of diseases where dysfunctional splicing drives disease development.

Citation

Batson, J., Toop, H. D., Redondo, C., Babaei-Jadidi, R., Chaikaud, A., Wearmouth, S. F., Gibbons, B., Allen, C., Tallant, C., Zhang, J., Du, C., Hancox, J. C., Hawtrey, T., Da Rocha, J., Griffith, R., Knapp, S., Bates, D. O., & Morris, J. C. (2017). Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease. ACS Chemical Biology, 12(3), 825-832. https://doi.org/10.1021/acschembio.6b01048

Journal Article Type Article
Acceptance Date Jan 30, 2017
Online Publication Date Feb 6, 2017
Publication Date Mar 17, 2017
Deposit Date Jul 11, 2017
Publicly Available Date Jul 11, 2017
Journal ACS Chemical Biology
Print ISSN 1554-8929
Electronic ISSN 1554-8937
Publisher American Chemical Society
Peer Reviewed Peer Reviewed
Volume 12
Issue 3
Pages 825-832
DOI https://doi.org/10.1021/acschembio.6b01048
Public URL https://nottingham-repository.worktribe.com/output/838564
Publisher URL http://pubs.acs.org/doi/abs/10.1021/acschembio.6b01048
Contract Date Jul 11, 2017

Files





You might also like



Downloadable Citations